Rate My Professor Loren Flynn
Ratings & reviews
Encourages open-minded and thoughtful discussions.
Challenges students to reach their potential.
Creates a collaborative learning environment.
Always kind, respectful, and approachable.
Taught by or worked with Loren?
Add your rating. It takes about 30 seconds.
About Loren
Dr. Loren Flynn is a Postdoctoral Scientist and Senior Lecturer at the Personalised Medicine Centre, Health Futures Institute, Murdoch University. She is also a Senior Research Fellow and co-leads the Motor Neurone Disease Genetics and Therapeutics Research group at the Perron Institute for Neurological and Translational Science alongside Professor Anthony Akkari. A molecular geneticist with 14 years of expertise, Dr. Flynn holds a BSc and PhD, completing her doctorate at the University of Western Australia and Perron Institute under Professors Steve Wilton and Sue Fletcher before joining the MND group in 2017. Her research centers on identifying and developing antisense oligonucleotide therapeutics targeting disease pathology in neurodegenerative conditions, including amyotrophic lateral sclerosis (ALS/MND) and Parkinson’s disease. She currently serves as Director for Therapeutic Development at Black Swan Biotech, advancing pre-clinical antisense therapy portfolios.
Dr. Flynn's contributions include leading efforts in genetic marker characterization for sporadic ALS and splice-modulating therapies. Notable publications encompass 'ALS Genetics, Mechanisms, and Therapeutics' (Genes, 2019), a highly cited review on ALS heritability and therapeutic targets; 'Genome-wide study of DNA methylation shows alterations in metabolic, inflammatory, and cholesterol pathways in ALS' (Science Translational Medicine, 2022); 'The SOD1-mediated ALS phenotype shows a decoupling...' (Nature Communications, 2022); 'Novel STMN2 Variant Linked to Amyotrophic Lateral Sclerosis Risk and Clinical Phenotype' (Frontiers in Aging Neuroscience, 2021); and 'Entering the era of precision medicine to treat amyotrophic lateral sclerosis' (Molecular Neurodegeneration, 2025). With over 35 publications and more than 1,800 citations, her work has attracted significant funding, including a $1 million FightMND grant in 2020 for MND treatment testing and further support in 2021. Through the Centre for Molecular Medicine and Innovative Therapeutics (CMMIT), she heads the MND/ALS research group, supervises doctoral students, and supports commercial therapeutic development, influencing precision medicine advances for neurodegenerative diseases via international collaborations.
Trending Research & Publication News
SPARC Cost of Knowledge Study: 95% Public Investment in Articles
Photo by Precondo CA on Unsplash
AI Research Scooping: OpenAI & Anthropic Priority Disputes
Photo by Brecht Corbeel on Unsplash
Informa Taylor & Francis Split & Clarion Deal | AcademicJobs
Photo by Anne Nygård on Unsplash
arXiv Two-Submission Monthly Cap Explained | AcademicJobs
Photo by Kelly Sikkema on Unsplash
Cell Press Bribery Investigation: Cancer Cell Editor Accused
Photo by Markus Winkler on Unsplash
Society Journal Sales & Nonprofit Consolidations | AcademicJobs
Photo by Philip Strong on Unsplash